cetuximab (Erbitux)
Jump to navigation
Jump to search
Introduction
Tradename: Erbitux FDA approved 2004
Indications
- adjuvant chemotherapy for colorectal carcinoma
- used in combination with irinotecan
- has not been shown to improve survival[2]
- cetuximab as single agent for colorectal carcinoma increases survival[3], 6.1 vs 4.6 months for supportive care
- head & neck cancer
- lung cancer
Adverse effects
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of EGF receptor inhibitors
- drug adverse effects of pharmaceutical monoclonal antibodies
Laboratory
- test for EGFR expression
- KRAS mutations
Mechanism of action
- monoclonal antibody to epidermal growth factor receptor (EGFR)
- inactive in colorectal cancer patients with KRAS mutations [4][6]
* ImClone drug implicated in Martha Stewart case (2004)
More general terms
References
- ↑ Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
- ↑ 2.0 2.1 FDA Approves Erbitux for Colorectal Cancer Prescriber's Letter 11(3):16,17 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200311&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Jonker DJ et al, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18003960
- ↑ 4.0 4.1 Lievre A et al, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18202412
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 15, 16. American College of Physicians, Philadelphia 2009, 2012
- ↑ 6.0 6.1 Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep. 2010 May;12(3):160-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20425075
Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010 Mar;32(3):437-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20399983